What do systematic reviews say?

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  OR 0.72 [0.58, 0.9]
  3 studies · 2445 participants
  Moderate

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  OR 0.62 [0.47, 0.82]
  1 study · 1206 participants
  Moderate

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  OR 0.75 [0.51, 1.1]
  1 study · 1206 participants
  Moderate

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  OR 0.77 [0.62, 0.96]
  1 study · 1791 participants
  Moderate

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  OR 0.87
  0 participants
  Low

Antioxidant multivitamin and mineral supplement vs placebo or no treatment

The review found no eligible studies for this question.

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found